1,2-Diaminocyclohexane Platinum Derivatives of Potential Clinical Value
Cisdiamminodichloroplatinum (DDP) has assumed an important role in clinical cancer chemotherapy either alone or, more often, in combination with bleomycin, adriamycin, Cytoxan (cyclophosphamide), vindesine, or the arabinosylcytosine (ara-C) derivatives. With these combinations, many investigators have reported on activity in germ cell tumors of the testis, carcinoma of the head and neck, penis, cervix, bladder, lung, esophagus, and ovary [1,7]. It has been used much less in the leukemias and lymphomas. Unfortunately, renal toxicity and severe nausea and vomiting have limited its usefulness, and compounds with less toxicity, greater antitumor effectiveness, and a broader spectrum of activity, including the leukemias and lymphomas, are being sought, particularly those lacking cross-resistance to DDP. As previously reported by various investigators [9, 13], the 1,2-diaminocyclohexane platinum derivatives seem to fit these criteria. In the experimental animal renal toxicity does not appear to be limiting , and in mouse leukemia there is no cross-resistance to DDP [2, 3]. The dichloro, malonato, and carboxyphthalato derivatives of 1,2-diaminocyclohexane platinum experimentally have shown a high degree of antitumor effectiveness [9, 13], marked synergism with ara-C derivatives, adriamycin, demethylepipodophyllotoxin ethylidene glucoside (VP-16) , and with cyclophosphamide, particularly in combination with various ribonucleotide reductase inhibitors such as hydroxyurea, guanazole, and MAIQ-1 . Clinically, the malonato derivative has been reported by HILL et al.  to be clinically active in the acute leukemias, and by RIBAUD et al.  to produce remissions in patients whose disease had become clinically resistant to DDP.
KeywordsLymphoma Platinum Leukemia Oncol Histamine
Unable to display preview. Download preview PDF.
- 6.Gale GR, Atkins LM, Meischen SJ, Schwartz P (1978) Schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia. Cancer Treat Rep 63:449–456Google Scholar
- 8.Hill JM, Loeb E, Pardue AS, Khan A, Hill NO, King JJ, Hill RW (1977) Platinum coordination compounds in the treatment of acute leukemia and other malignant diseases with particular reference to malonato 1,2-diaminocyclohexane platinum (II). J Clin Hematol Oncol 7:681–700Google Scholar
- 11.Ribaud P, Alcock N, Burchenal JH, Young CW, Muggia F, Mathe G (1979) Preclinical trial in baboon and phase I-II trial and pharmacokinetics in man of malonato platinum (MP). Proc Am Soc Clin Oncol 20:336, abstr #C-186Google Scholar
- 12.Schindler RS, Day SM, Fischer GA (1958) Culture of neoplastic mast cells and their 5-hydroxytryptamine and histamine content in vitro. Fed Proc 17:1617Google Scholar